Novo CSO: New obesity treatment might prove as effective as surgery

Danish Novo Nordisk's new obesity candidate brings the company one step closer to the dream of developing a medical treatment that is as effective as surgery, says CSO Mads Krogsgaard Thomsen.

Photo: /ritzau/Peter Hove Olesen

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles